The long-term transformative potential of cell and gene therapies has become increasingly clear in recent years, and it is equally apparent that bringing innovative therapies to patients faces no shortage of roadblocks. Therefore, providing solutions to the challenges of manufacturing cell and gene therapies has never been so significant as an increasing number of products head towards commercialization. Key challenges include developing manufacturing processes that deliver a high-quality product with a reasonable cost of goods, which are also scalable to meet the changing demands throughout the full product life-cycle.
Watch this On Demand webinar to hear about the latest advances and technologies developed by Lonza for next-generation cell & gene therapy manufacturing, with real life examples and best practises, and gain insight into:
- Advanced technologies and platforms that enable processes for cell therapies which are robust, repeatable, and cost-efficient;
- Current approaches to commercial-scale manufacture of cell therapy products and the unique challenges and limitations of each;
- Transitioning cell therapy products from development through to GMP manufacturing and commercial success;
- Current manufacturing techniques for the generation of pluripotent stem cells.
The Lonza logo is a Lonza Ltd. Trademark
Yonatan Levinson
Research & Development Scientist, Lonza
Yoni Levinson is a Senior Scientist who joined Lonza in 2016 to lead the allogeneic cell therapy R&D group. Yoni’s group focuses on bioreactor technologies for cell therapy, as well as novel scaffolds and Process Analytical Technology. Prior to Lonza, Yoni worked in cell therapy process development around 3D bioreactors.
Thomas Richardson
Bioprocess Scientist in Cell Therapy Process Development, Lonza
Thomas Richardson is a Bioprocess Scientist in Cell Therapy Process Development, part of the Emerging Technologies Division of Lonza. He earned his PhD in Chemical Engineering from the University of Pittsburgh, where his dissertation work concentrated on the development of novel propagation techniques for the scalable culture of human pluripotent stem cells (hPSCs). In particular, he focused on the effect of biomaterial encapsulation on the pancreatic differentiation of hPSCs to support biomanufacturing of hPSC-derived insulin producing cells. At Lonza his work has focused on the development of GMP cell therapy processes with autologous and allogeneic cell sources and utilizing a myriad of devices such as multi-layered planar vessels and stirred-suspension bioreactors. His talk will provide an overview of some these exciting technologies as well as discuss the specific challenges faced in developing GMP manufacturing processes for cell-based therapies and how Lonza is addressing them.
Inbar Friedrich Ben-Nun
Senior Manager at Cell Therapy Research and Development, Lonza
Dr. Inbar Friedrich Ben-Nun is a Sr. Manager at Lonza Cell Therapy Research and Development. Inbar obtained her MSc and PhD in Molecular and Structural Biochemistry at the Hebrew University of Jerusalem, Israel. As a postdoctoral fellow at the Scripps Research Institute, CA, she acquired extensive experience with pluripotent stem cells. Her work, published in “Nature Methods” showed for the first time that stem cell research could be applied to save species from extinction. At Lonza she focuses on developing innovative methods and platforms to enhance the enabling of stem cell-based cell therapies.
